Table 2.
Tumor response at 1, 3, 6 month between the two groups
| Main outcome | One-month | Three-month | Six-month | ||||||
|---|---|---|---|---|---|---|---|---|---|
| TACE (n = 28) | TACE–MWA (n = 17) | P value* | TACE (n = 28) | TACE–MWA (n = 17) | P value* | TACE (n = 28) | TACE–MWA (n = 17) | P value* | |
| Tumor response | 0.044 | 0.020 | 0.011 | ||||||
| CR | 12 (42.8%) | 14 (82.4%) | 12 (42.8%) | 14 (82.4%) | 7 (25%) | 13 (76.5%) | |||
| PR | 8 (28.6%) | 3 (17.6%) | 5 (17.9%) | 1 (5.9%) | 7 (25%) | 1 (5.9%) | |||
| SD | 4 (14.3%) | 0 | 3 (10.7%) | 2 (11.7%) | 5 (17.9%) | 1 (5.9%) | |||
| PD | 4 (14.3%) | 0 | 8 (28.6%) | 0 | 9 (32.1%) | 2 (11.7%) | |||
| ORR | 20 (71.4%) | 17 (100%) | 17 (60.7%) | 15 (88.2%) | 14 (50%) | 14 (82.3%) | |||
| DCR | 24 (85.7%) | 17 (100%) | 20 (71.4%) | 17 (100%) | 19 (67.9%) | 15 (88.2%) | |||
TACE transarterial chemoembolization, MWA microwave ablation, CR complete response, PR partial response, SD stable disease, PD progressive disease; objective response rate (ORR) = CR + PR; disease control rate (DCR) = CR + PR + SD
*Fisher exact test was used